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Pneumocystis pneumonia (PCP) is caused by the yeast-like fungus 
Pneumocystis. Despite the widespread availability of specific anti-Pneumocystis 
prophylaxis and of combination antiretroviral therapy (cART) PCP remains a common 
AIDS-defining presentation in the United States and in Europe. PCP is increasingly 
recognized among persons living in Africa. Pneumocysits cannot be cultured and 
bronchoscopic alveolar lavage is the “gold standard” diagnostic test to diagnose 
PCP. Use of adjunctive biomarkers for diagnosis requires further evaluation. 
Trimethoprim-sulfamethoxazole remains the preferred first-line treatment regimen. In 
the era of cART mortality from PCP is approximately 10-12%. The optimal time to 
start cART in a patient with PCP remains uncertain. 
 
Introduction 
Different species of the Ascomycetous yeast-like fungus Pneumocystis 
asymptomatically infect/colonize numerous healthy mammalian hosts and in immune 
compromised mammals (including humans) can cause a potentially life-threatening 
pneumonia (PCP). The organism is host-obligate and species specific: it cannot be 
grown outside the host and organisms from one host cannot infect other mammalian 
hosts [1].                                                                                                                                                                           
Pneumocystis was identified in 1909 by Chagas, who mistakenly described it 
as part of the life cycle of the protozoan parasite Trypanosoma cruzii. It was first 
recognized as a human pathogen when it was described as the cause of “interstitial 
plasma cell pneumonia” among premature/malnourshised infants in European 
orphanages immediately after WW2. In the 1960s and 1970s descriptions of PCP 
were mainly in children with congenital immunodeficiency and also among 
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adults/children with acquired immunological deficits resulting from malignancy 
(specifically, glioma, and acute leukemia) or its treatment (with glucocorticoids and 
purine analogues). The advent of organ transplantation and iatrogenic 
immunosuppression in the 1960s was associated with reports of PCP among this 
patient population. 
        In 1981 description of PCP in 15 previously healthy men who had sex with other 
men and/or who were injection drug users heralded the advent of the global 
HIV/AIDS pandemic [2][3]. Despite the availability of prophylaxis and of combination 
antiretroviral therapy (cART) PCP remains an important clinical presentation among 
HIV-infected persons [4]. 
 
Epidemiology of HIV-associated PCP  
Before the onset of the AIDS epidemic PCP was uncommon in the United 
States; between November 1967 and December 1970 194 patients were reported to 
Centers for Disease Control [5], and in the 1970s fewer than 100 cases per year 
were seen in the United States. During the early years of the AIDS epidemic, PCP 
accounted for two thirds of AIDS-defining illness in patients in the United States, and 
an estimated 75% of HIV-infected patients developed PCP during their lifetime [6][7]; 
rates of PCP were as high as 20 per 100 person-years among those with CD4 cell 
counts <200 cells/µL [7][8]. 
The first substantial decline in the incidence of PCP occurred after the 
introduction of anti-Pneumocystis prophylaxis in 1989 [9]. In the United States 
because of an increasing incidence of AIDS from 1989 to 1992, absolute numbers of 
reported cases of PCP as an AIDS-defining illness remained stable, but the 
percentage with PCP declined, from 53% in 1989 to 42% in 1992, respectively [7].  
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The advent of cART resulted in further declines in rates of PCP and other 
opportunistic infections [7][10][11]. Several large, multicenter studies have tracked 
the incidence and epidemiologic features of PCP in the era of cART. Data from the 
Adult and Adolescent Spectrum of HIV Disease (ASD) study showed a marked 
reduction in incidence of all opportunistic infections in 1996 and 1997, when cART 
first became widely available; from 1992 to 1995 cases of PCP declined by 3.4% per 
year, and from 1996 to 1998 declined by 21.5% per year [7][11]. Multicenter AIDS 
Cohort Study also showed a marked reduction in opportunistic infections after 
introduction of cART  [12] 
In Europe, the EuroSIDA study has examined changes in incidence of AIDS-
defining disease before and after cART was introduced (1994–1998) and found 
results similar to those in the United States. The incidence of PCP fell from 4.9 cases 
per 100 person-years before March 1995 to 0.3 cases per 100 person-years after 
March 1998 [13][14]. 
Despite these improvements, data from the Hospital Outpatient study (HOPS) 
shows that PCP remains the second most common AIDS-defining opportunistic 
infection in the United States; in 1994-1997 the incidence was 29.9 per 1000 person-
years, and fell to 7.7 and 3.9 per 1000 person-years, in 1998-2002 and 2003-2007, 
respectively [14]. In the United Kingdom PCP was the commonest AIDS-defining 
illness in the decade 2001-2010 [16]. 
In the United States, Western Europe and Australasia PCP still occurs among 
HIV-infected persons despite the availability of cART and anti-Pneumocystis 
prophylaxis. The ASD study examined use of PCP prophylaxis among HIV-infected 
adults who developed PCP during 1999-2001 [12].  More than 43% of PCP cases 
occurred in persons not receiving medical care, the majority of who were likely not 
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known to be HIV-infected, and a further 41% were prescribed prophylaxis but were 
either non-adherent with treatment, or PCP developed despite treatment adherence. 
Possible explanations for PCP in this group include decreased efficacy of prophylaxis 
among those with low CD4 counts and development of drug-resistant Pneumocystis. 
An additional 9.6% were under medical care but did not receive prophylaxis, based 
on current recommendations (i.e. CD4 count >200 cell/ul, or >14% of total 
lymphocyte count) [17]. 
In the pre-cART era the greatest risk factor for PCP in an HIV-infected person 
was a CD4 cell count <200 cells/µL; this remains an important risk factor in the cART 
era. The lower the CD4 count falls below 200 cells/µL the risk for PCP increases 
exponentially [18]. Those who develop PCP despite receipt of cART usually have a 
low CD4 count. In the ASD study the CD4 count among persons developing PCP 
while receiving cART was low (median=29 cells/µL), and was lower among those not 
taking cART (median=13 cells/µL) [11]. The prospective pan-European EuroSIDA 
study reported that the median CD4 count was 30 cells/µL among persons 
developing PCP while receiving cART, and was similar among those not receiving 
cART who got PCP [8]. Patients without improvement in their CD4 count after 
starting cART remain at risk for PCP. One recent study showed that approximately 
5% of HIV-infected persons have a CD4 count >200 cells/µL at presentation with 
PCP [19]. 
Other clinical risk factors for development of PCP include gender, race or 
ethnicity, and risk factor for HIV acquisition. Men are more likely than women to 
develop PCP [17]; one study demonstrated that African Americans have a lower risk 
for PCP than white persons [17] but this finding has not been replicated [10] MSM 
appear to be at equal risk, when compared with other risk exposure groups [10]. 
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PCP still occurs frequently among HIV-infected patients in many parts of the 
developing world [20]. Studies from Thailand show the prevalence of PCP is up to 
40% [21]. Central and South America also report large numbers of PCP cases. One 
Brazilian study found that 55% of HIV-infected persons with respiratory symptoms 
had PCP [22], another study from Mexico reported a 24% PCP prevalence [23]. 
By contrast, PCP has until recently been thought to be rare in African adults. 
However, high rates of anti-Pneumocystis antibodies among African children suggest 
that exposure to the organism is common, and PCP is a common cause of 
pneumonia among children in Sub-saharan Africa [24]. PCP might have been under-
reported in Africa for several reasons. Limited local diagnostic resources, including 
lack of trained clinical and laboratory personnel and expensive equipment mean that 
invasive investigations such as induced sputum and bronchoscopic alveolar lavage 
are less commonly performed, and reliance on empiric therapy of HIV-infected 
persons with presumed PCP potentially results in under-estimation of the true 
incidence of PCP. Many HIV-infected African adults may not reach a stage at which 
they would be susceptible to PCP as these populations have high rates of 
tuberculosis and bacterial pneumonia that may result in death at higher CD4 counts. 
Environmental factors, such as temperature and seasonality, might also contribute to 
a low rate of PCP in Africa. The population may be more resistant to development of 
PCP; HIV-infected African Americans have been shown to have lower rates of PCP 
than white Americans [18]; or P. jirovecii strains isolated in Africa may be less 
virulent, a possibility that can only be answered by large-scale molecular 
epidemiologic studies. 
As the AIDS epidemic progresses in Africa most, but not all studies suggest 
that the incidence of PCP is increasing [20][24][25][26][27]; it is unclear whether this 
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increase results from changes in incidence of PCP or from improvements in detection 
techniques.  
Pathogenesis  
Studies in animal models have demonstrated that Pneumocystis is 
communicable via the airborne route. Young animals acquire Pneumocystis infection 
soon after birth and have an important role in spreading infection. Molecular 
epidemiologic studies in humans support the findings from these experimental 
models [28][29]. The human incubation period from inhalation to presentation with 
PCP is thought to be approximately 4 to 8 weeks. 
The majority of healthy adults do not have detectable Pneumocystis in 
respiratory specimens [30][31], but several groups of individuals, both HIV-infected 
and uninfected infected, including those with chronic obstructive pulmonary disease 
(COPD), and pregnant women may become colonized with Pneumocystis, thus 
increasing the potential number of persons affected [32][33][34]. Pneumocystis 
colonization may increase the risk for progression to PCP among HIV-infected and 
uninfected persons. Persons colonized with Pneumocystis may also transmit 
infection to others who have minor or significant immune suppression, and as such 
act as an “infectious reservoir”. Long-term colonization of asymptomatic HIV-infected 
and uninfected (eg COPD) hosts may result in pulmonary inflammation and 
progressive impairment of lung function [33][35][36].  
After inhalation, Pneumocystis eludes the upper airway defenses and deposits 
in alveoli: where it adheres tightly to alveolar type I cells, and provokes a host 
inflammatory response [36]. In the majority of hosts with an intact immune system the 
organism is rapidly coughed out. If the host has any underlying “minor” immune 
suppression/HIV-associated immunodeficiency, colonization with Pneumocystis 
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ensues [34][35]. If the host then becomes more immune compromised, by 
progression of HIV, or by additional therapeutic immune supression then 
Pneumocystis propagates within the alveoli, and slowly “floods them out.” At the 
same time disruption of the alveolar-capillary membrane, with ventilation-perfusion 
abnormalities similar to changes seen in acute respiratory distress syndrome, also 
occur and manifest as impaired gas exchange. These events culminate in 
presentation with PCP; in humans PCP is caused by Pneumocystis jirovecii; 
Pneumocystis carinii is the cause of PCP in rats.   
  
Clinical manifestations 
The clinical presentation of PCP among HIV-infected patients is non-specific 
and can be mimicked by a wide variety of infectious and non-infectious etiologies. 
Patients typically present with a triad of progressive exertional dyspnea, 
nonproductive cough, and fever of several days or weeks duration, which is often 
associated with an inability to take in a maximum inspiration (not due to pain) 
[37][38]. Although a productive cough and chest tightness may occur, purulent 
sputum should raise suspicion of bacterial infection. Hemoptysis is not a feature. 
Among HIV-infected persons, symptoms are usually of longer duration than among 
medically-immunosuppressed patients [39]. HIV-infected patients frequently have 
prolonged prodromal periods with subtle clinical manifestations developing over 3-8 
weeks, however some individuals present with a fulminant deterioration of symptoms 
over 7-10 days, or less. On physical examination varying degrees of respiratory 
distress (tachycardia, central cyanosis) may be evident as well as stigmata of 
immune suppression, including oral hairy leukoplakia, molluscum contagiousum, 
seborrhoeic dermatitis and cutaneous Kaposi sarcoma; auscultation of the chest is 
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In early PCP, the chest radiograph may be normal; with later presentations, 
and with more severe disease, diffuse perihilar interstitial infiltrates are seen (Figure 
1). These appearances may progress to diffuse bilateral air space (alveolar) 
consolidation resembling pulmonary edema. With delayed presentation or untreated 
severe disease, there may be confluent alveolar shadowing (“white out”) throughout 
both lungs, with sparing of the costophrenic angles and apices (Figure 2). The chest 
radiographic appearances in PCP may change rapidly from normal at presentation to 
markedly abnormal over a period of only 2–3 days (Figure 3a, Figure 3b). Atypical 
radiographic features include cystic air space and pneumatocele formation, unilateral 
consolidation, lobar infiltrates, nodules, mediastinal lymphadenopathy, pleural 
effusions and upper zone infiltrates resembling tuberculosis (Figure 4). 
Although the chest radiograph is a sensitive way of detecting PCP, it is non-
specific; these typical and atypical radiographic appearances are also seen in other 
fungal, mycobacterial and bacterial infections, and in non-infectious conditions, such 
as interstitial pneumonitis and pulmonary Kaposi sarcoma. With treatment of PCP, 
improvements in the chest radiographic appearances are not usually apparent for 7–
10 days. After clinical recovery, some radiographs show residual fibrosis or post-
infectious bronchiectasis. 
 
High-resolution computed tomography 
This may be useful in the symptomatic patient with suspected PCP who has a 
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normal or equivocal chest radiograph. Patches of “ground glass” shadowing are 
typical for PCP, but also occur in viral (eg cytomegalovirus, influenza A) or fungal 
pneumonia and in occult alveolar hemorrhage (Figure 5). 
 
Arterial blood gases 
In patients presenting early with PCP, even though the arterial oxygen tension 
(PaO2) may be normal or near normal, respiratory alkalosis with hypocarbia 
(indicating hyperventilation) is often detected; hypoxia may occur with progression of 
the PCP. The alveolar- aO2) is widened in >90% of 
patients with PCP, but this finding, although suggestive, is non-specific as both 
hypox aO2 gradient also occur in bacterial and mycobacterial 
infection, non-specific interstitial pneumonitis and pulmonary Kaposi sarcoma. 
 
Exercise oximetry 
Among HIV-infected patients, not in receipt of cART, and who have respiratory 
symptoms, a normal or near-normal chest radiograph and normal resting PaO2 
values, exercise-induced arterial desaturation is a sensitive and specific method of 
detecting PCP. A normal exercise test (without desaturation) virtually excludes the 
diagnosis. 
 
Pulmonary function testing 
Data from the North American Pulmonary Complications of HIV infection 
Study suggest that HIV-individuals who are not in receipt of cART and who have 
rapid rates of decline in DLCO are at an increased risk for development of PCP [18]. 
A normal DLCO in an individual who has respiratory symptoms but a normal or 
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unchanged chest radiograph makes the diagnosis of PCP extremely unlikely.  
 
Serum lactate dehydrogenease 
An elevated serum lactate dehydrogenase (LDH) level is highly suggestive of 
PCP in an HIV-infected patient with sub-acute respiratory symptoms [40]. However 
an elevated serum LDH is non-specific as it is also found in other pulmonary 
diseases, including pulmonary embolism, non-specific interstitial pneumonitis, fungal, 
bacterial and mycobacterial pneumonia, as well in extra-pulmonary disease, such as 
multicentric Castleman disease and lymphoma. 
 
Serum (1-3) ß-D-glucan 
Measurement of the fungal cell wall component (1-3) ß-D-glucan (BG) in 
serum has been used as an adjunctive diagnostic tool for diagnosis of PCP [41][42]. 
BG levels are higher among both HIV-infected and uninfected patients with PCP, 
when compared with symptomatic patients with confirmed alternative diagnoses, 
including aspergillosis and histoplasmosis. False positive results occur in bacterial 
pneumonia, patients undergoing hemodialysis, and those who recently received 
intravenous immunoglobulin. Currently, the serum BG assay appears to be a 
promising adjunctive non-invasive test for diagnosis of PCP, but further validation is 
needed before it can it be used to monitor treatment response in PCP, as despite 
clinical recovery, reductions in BG titer are both delayed and unpredictable [43]. 
 
Plasma/serum S-adenosylmethionine 
Pneumocystis lacks S-adenosylmethionine synthetase, is unable to 
metabolize S-adenosylmethionine (SAM, or Adomet), and so ‘scavenges’ this from 
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the human host. It was hypothesized that HIV-infected persons with PCP would have 
low serum/plasma SAM levels. Whereas measurement of plasma SAM levels 
enabled discrimination between PCP and “other” causes of pneumonia in some 
studies [44], one study showed overlapping serum SAM levels [45]. Currently, this 




Pneumocystis is rarely identified in spontaneously expectorated sputum. 
Induced sputum, obtained by inhalation of an aerosol of hypertonic saline is a useful 
screening technique. The diagnostic yield from this technique varies considerably 
between centers. Supervison of the procedure by an experienced nurse or 
respiratory therapist increases the yield; a negative result for Pneumocystis from 
sputum induction should prompt referral for bronchoscopy. 
 
Fibreoptic bronchoscopy 
Fibreoptic bronchoscopy with bronchoscopic alveolar lavage (BAL) has a high 
diagnostic yield, >90% for detection of PCP. Transbronchial biopsy adds little to 
diagnosis, and is associated with complications, including pneumothorax and 
hemorrhage. Treatment should never be deferred in an HIV-infected person with 
suspected PCP pending results of bronchoscopy, as significant clinical deterioration 
may occur. The yield for diagnosis of PCP from BAL fluid is not reduced for up to 14 
days after starting treatment.  
 
Video-Assisted thoracoscopic biopsy 
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This is occasionally performed in HIV-infected patients with suspected PCP 
and who have negative results from ≥2 bonchoscopies, and among patients whose 
clinical course is at variance with laboratory-confirmed PCP. 
 
Histologic diagnosis 
  Pneumocystis cannot reliably be cultured ex vivo, and so diagnosis of PCP is 
by microscopic visualization of the organism in BAL fluid, induced sputum, or lung 
tissue. Histopathologically, PCP is characterized by the presence of a foamy, 
vacuolated exudate filling alveoli. With late presenting or severe disease, there may 
be interstitial fibrosis, edema, and development of hyaline membranes. Hypertrophy 
of type II alveolar cells, inferring tissue repair, is frequently seen. 
Several histologic stains have been used to identify Pneumocystis. Stains that 
identify the wall of the cystic form (methenamine silver, toluidine blue O and cresyl 
violet), are widely used as they require minimal laboratory expertise and are easily 
interpreted, and stains that demonstrate the nuclei of all Pneumocystis 
developmental stages (Diff-Quik or Wright-Geimsa) can provide a rapid diagnosis 
(within minutes) but require laboratory expertise. Other reagents, including 
Papanicolaou and calcofluor white, a chemiluminescent agent, are used by some 
laboratories. 
Use of Pneumocystis-specific monoclonal antibodies and immunofluorescence 
has greater diagnostic sensitivity than histologic stains, but is more expensive and 
requires specific laboratory expertise.  
 
Molecular detection tests  
Detection of Pneumocystis-specific DNA using the polymerase chain reaction 
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in BAL fluid and induced sputum is superior to histologic staining for diagnosis of 
PCP. Pneumocystis DNA may also be detected in oropharyngeal wash (OPW) 
samples in HIV-infected persons presenting with PCP. The specificity and clinical 
significance of molecular detection assays is impaired by the finding of Pneumocystis 
DNA in respiratory samples (BAL fluid, induced sputum, or OPW) from HIV-infected 
patients without respiratory symptoms, and in symptomatic persons without PCP with 
confirmed alternative diagnosis who are colonized with Pneumocystis. Currently, the 
clinical significance of detectable P. jirovecii DNA (representing colonization) in a 
respiratory sample from an HIV-infected person in the absence of respiratory 
symptoms or other confirmatory tests is unclear. 
Although PCR is not licensed for diagnosis, several clinical laboratories in the 
United States and Europe use this method applied to invasive (BAL and Induced 




Empirical therapy for HIV-infected patients presenting with symptoms, chest 
radiographic and arterial blood gas abnormalities typical of PCP is used in healthcare 
settings that lack diagnostic facilities. This strategy is possible if a patient with a CD4 
<200 cells/uL (or stigmata of immune suppression) has typical radiological 
abnormalities, is not receiving Pneumocystis prophylaxis or cART, and has a low 
probability of other (opportunistic) infections, such as tuberculosis [38].  
 
Treatment 
An assessment of the severity of the pneumonia, using the results of arterial 
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blood gas estimations, will enable decisions to be made about choice of therapy; 
some drugs are unproven or ineffective in severe disease.  When breathing room air, 
PaO2 >70mmHg (>9.3 kPa) indicates mild PCP, and <70 mmHg (<9.3 kPa) indicates 
moderate to severe PCP. Alternatively, A-aO2 an gradient <35 mmHg, 35-45 mmHg, 
and, >45 mmHg (>6 kPa) indicates mild, moderate and severe PCP, respectively. 
Severity stratification also identifies patients who will benefit from adjunctive 
glucocorticoids (see below).  
Patients with glucose 6-phosphate dehydrogenase deficiency should not 
receive TMP-SMX, dapsone, or primaquine as they increase the risk of hemolysis. 
 
Trimethoprim-sulfamethoxazole  
Trimethoprim-sulfamethoxazole (TMP-SMX), [Bactrim, Bactrimel, Co-
trimoxazole, Cotrim, Septra, Septrin, Sulfatrim,Trisul]  (20 mg/kg daily of TMP and 
100 mg/kg daily of SMX ) given in two to four divided doses orally or intravenously is 
first choice therapy for PCP of all grades of severity; this drug combination acts by 
inhibiting folic acid metabolism. In HIV-infected patients treatment is given for 21 
days because shorter courses are associated with treatment failure. In patients with 
moderate or severe disease, TMP-SMX is given intravenously for the first 7–10 days, 
then orally; in patients with mild disease oral TMP-SMX may be given throughout. 
This treatment regimen is effective in 70-80% of patients. Adverse reactions to TMP-
SMX, which are usually first evident at 6–14 days of treatment, are common and 
include neutropenia and anemia in ≤40% of patients, rash in 25%, fever in >30% and 
abnormal liver function tests in approximately 10% [49][50]. 
Co-administration of folic or folinic acid does not reduce or prevent 
hematologic toxicity and may be associated with increased therapeutic failure. Dose 
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reduction of TMP-SMX, to 75% of the dose given above, is associated with a 
reduced toxicity profile but may be associated with reduced efficacy. It is not clear 
why there is such a high frequency of adverse reactions to TMP-SMX among HIV-
infected patients compared to patients immunosuppressed by other causes, but it 
may be due to HIV-induced changes in acetylator status, accumulation of toxic 
metabolites such as hydroxylamines, or to glutathione deficiency. 
 
Alternative therapy 
Several other treatments are available if TMP-SMX is not tolerated by the 
patient or if treatment fails [17]. 
 
Clindamycin and primaquine 
This combination was originally only used to “salvage” patients with mild and 
moderately severe PCP failing TMP-SMX or pentamidine. It is now used as 
alternative therapy in patients with PCP of all severity. Clindamycin (Cleocyin, Daclin) 
450–600 mg four times daily is combined with primaquine 15 mg daily (orally). 
Clindamycin is usually given intravenously for the first 7–10 days, then orally in 
moderate and severe disease; the treatment may be given orally throughout in 
patients with mild disease. The mechanism of action of this combination is not 
known. Clindamycin-primaquine is as effective as TMP-SMX or dapsone-
trimethoprim (see below) when given as initial treatment for patients with PCP of mild 
and moderate severity and is superior to intravenous pentamidine when used in 
patients intolerant of, or who are failing treatment with TMP-SMX [51]. Almost two-
thirds of patients develop a rash and approximately quarter develop diarrhea (both 
caused by clindamycin). Analysis of stool for detection of Clostridium difficile is 
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indicated if diarrhea occurs. Methemoglobinemia (due to primaquine) occurs in 
≤40% of patients, but this is less likely if 15mg rather than 30mg of primaquine is 
used. 
 
Dapsone with trimethoprim 
Among patients with mild or moderate severity PCP a combination of oral 
dapsone (Axzone) (100 mg per day) and TMX (20 mg/kg daily) is as effective as 
TMP-SMX (doses as above) and is better tolerated. Rash, nausea and vomiting, mild 
hyperkalemia (caused by trimethoprim, in ≤50%) and asymptomatic 
methemoglobinemia (caused by dapsone) are common side-effects. This 
combination has not demonstrated efficacy in severe PCP. 
 
Atovaquone 
Oral atovaquone (Mepron) is a hydroxynaphthoquinolone that acts against 
Plasmodia by inhibiting electron transport. At a dose of 750 mg twice daily it is 
ineffective in patients with severe PCP and less effective than either oral TMP-SMX 
or intravenous pentamidine for treatment of mild and moderate severity PCP, but is 
better tolerated than either drug. Adverse reactions include fever, rash, nausea and 
vomiting, constipation and abnormal liver function tests.  
 
Parenteral pentamidine 
Intravenous pentamidine (Pentacarinat, Pentam 300, pentamidine isethionate 
for injection) is now rarely used in mild and moderately severe PCP.  Its mode of 
action against Pneumocystis is unknown. It continues to be used in patients with 
severe PCP. It is given at a dose of 4 mg/kg daily, by intravenous infusion over at 
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least one hour. Compared with TMP-SMX, intravenous pentamidine has almost 
equivalent efficacy but greater toxicity; ≤60% of patients develop increases in the 
serum creatinine level; approximately half develop leucopenia. Hypotension and 
nausea/vomiting both occur in up to a quarter of patients; hypoglycemia occurs in 
approximately 20%; cardiac dysrhythmias (toursade de points) pancreatitis, 
hypocalcemia, and hypomagnesemia are also described. Autopsy data suggests that 
it takes at least five days for pentamidine to reach therapeutic concentrations in the 
lung. Using a dose of 3mg/kg daily is associated with fewer ADR, but data showing 
equivalent efficacy with the 4mg/kg dose are lacking. There are no therapeutic 
advantages to combining TMP-SMX and intravenous pentamidine and this 
combination has a much higher toxicity profile. 
 
Caspofungin 
Caspofungin (Cancidas) is an echinocandin that inhibits (1-3)-ß-D-glucan 
synthase and is effective against Aspergillus and Candida spp. Several case reports 
and small case series show that caspofungin as monotherapy or combined with other 
therapy, may be effective in patients with PCP who are not responding or tolerating 
first-line therapy. Caspofungin has not been prospectively evaluated against TMP-
SMX or other regimens as first-line therapy. 
 
Nebulized pentamidine 
This has no role in treatment of PCP. 
 
Adjunctive Corticosteroids 
In HIV-infected patients with moderate and severe PCP adjunctive therapy 
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with corticosteroids has been shown to reduce the likelihood of respiratory failure (by 
half) and death (by one-third). Corticosteroids probably act by reducing the body’s 
intrapulmonary inflammatory response to Pneumocystis. It is recommended that 
glucocorticoids are given to HIV-infected patients with proven or suspected PCP who 
have a PaO2  <70mmHg (< 9.3 kPa) or A aO2 >35 mmHg (>4.7 kPa) [17]  
Corticosteroid treatment should begin at the start of specific anti Pneumocystis 
therapy. In some patients treatment will begin on a empiric basis and the diagnosis 
should be confirmed as soon as practicable. Regimens include oral prednisolone 
40 mg twice daily for 5 days, thereafter 40 mg once daily for days 6–10 and then 10 
further days of 20 mg daily and intravenous methylprednisolone at 75% of these 
doses [17]. There is no evidence that adjunctive corticosteroids are of benefit in 
patients with mild PCP. Patients receiving adjunctive corticosteroids should be 
monitored for hyperglycemia. In the long term patients receiving this intervention are 
at greater risk of developing avascular necrosis of the hip. 
 
General management 
In the first few days of of treatment HIV-infected patients with PCP may experience a 
deterioration in their clinical condition, with worsening of the chest radiograph and 
oxygenation. This is thought to arise either from the host inflammatory response to 
dying Pneumocystis, or to Pneumocystis-induced changes in surfactant leading to 
worsening of lung injury.  
Patients with mild PCP may be treated as outpatients with oral TMP-SMX 
under close supervision of a physician. Patients with moderate and severe PCP 
should be treated with intravenous TMP-SMX, or with clindamycin with primaquine, 
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and adjunctive corticosteroids. Patients not responding by 5–7 days should be 
switched to alternative therapy. Before ascribing deterioration to treatment failure and 
considering a change in therapy, evaluation for alternative causes should be done 
(Table). Additionally, is important to perform bronchoscopy if the diagnosis is empiric, 
and to treat any co-pathology already detected in BAL fluid. 
All hypoxemic patients with PCP should receive supplemental oxygen therapy 
via a tight-fitting facemask in order to maintain the PaO2 ≥60mmHg (≥8.0 kPa). If an 
inspired oxygen concentration of 60% fails to maintain the PaO2 ≥ 60mmHg 
(≥8.0 kPa), referral to the ICU for mechanical ventilation should be considered. The 
prognosis of patients with severe PCP with respiratory failure has improved in recent 
years, as a consequence of general improvements in ICU management of respiratory 
failure [52] [53]. Most centers would mechanically ventilate patients with a first or 
second episode of PCP and those who rapidly deteriorate following bronchoscopy.  
 
Prognosis 
Over the last 20 years the outcome for HIV-infected persons with PCP has 
improved. This is likely due to a combination of earlier detection of disease, timely 
institution of treatment and more effective management of complications. In the cART 
era mortality from PCP is 9.7-11.6% [19][54][55]. Several clinical and laboratory 
features have been shown predict a poor outcome among HIV-infected patient with 
PCP. Prognostic factors include at presentation, increasing patient age, lack of 
knowledge of HIV status, presentation with a second or subsequent episode of PCP, 
evidence of poor oxygenation (PaO2 53 mmHg (<7.0 kPa) or an aO2 gradient 
>30 mmHg (>4.0 kPa), marked chest radiographic abnormalities, peripheral blood 
x 109/L), a low hemoglobin (<12 g/dL), a 
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 g/L), and raised serum lactate dehydrogenase (LDH) 
 IU/L). After admission and investigation, identification in BAL 
fluid of a (viral, eg CMV, or bacterial) co-pathogen,  or elevated IL-8 
levels, evidence of fibrosis and edema on transbronchial biopsy, and elevated serum 
LDH enzyme levels (that do not fall despite treatment), identification of co-morbidity 
eg non-Hodgkin lymphoma, presence of pulmonary Kaposi sarcoma, or admission to 
the intensive care unit (ICU), a high APACHE II (Acute Physiology and Chronic 
Health Evaluation) score, need for mechanical ventilation, and/or development of a 
pneumothorax are also predictive of a poor outcome. 
Several prognostic scores have been derived from factors present at/soon 
after an HIV-infected person’s presentation with PCP; scores based on wasting, A-
aO2 gradient, and serum albumin, [56]; age, injection drug use, A-aO2 gradient, 
serum albumin and serum bilirubin [57]; age, hemoglobin, PaO2, pulmonary Kaposi 
sarcoma, and co-morbidity [58] all associate with mortality. The potential value of 
such prognostic scores lies in their ability to identify those at greatest risk of death 
and to inform clinicians about which patients can safely be managed in an outpatient 
setting. While these prognostic scores have been derived from large cohorts of HIV-
infected patients with PCP in the United States or United Kingdom, none has ben 
validated in other US/UK cohorts nor in developing-world settings[56][57][58]. 
 
Starting antiretroviral therapy in a patient with PCP 
The optimal time to initiate cART in a person with PCP remains to be 
determined; some clinicians start cART immediately while others prefer to see a 
clinical response to PCP treatment. One randomized trial of patients with 
opportunistic infection (OI), approximately two-thirds of whom had PCP, 
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demonstrated that cART when initiated early (within 2 weeks) and compared to 
therapy deferred until ≥4 weeks after initiation of treatment for the OI was associated 
with a significant reduction in mortality, but no increased risk of IRIS [59] [60]. While 
this study supports early cART, it does not show whether immediate treatment at 
time of PCP diagnosis or waiting for a response to PCP treatment (usually within 4–7 
days) is a better strategy. Of note, the study excluded those with severe laboratory 
abnormalities and required patients to be able to take oral medication - mechanically 
ventilated patients were not studied - inferring possible selection bias in favor of less 
sick patients. By contrast, marked respiratory deterioration from cART, if initiated 
early, has been reported [61]. 
 
Prophylaxis 
With progressive immunosuppression and falls in CD4 counts, HIV-infected 
individuals are at increased risk of developing PCP. Primary prophylaxis, to prevent a 
first episode of PCP, is 
the CD4:total lymphocyte ratio is less than 1:5 (or <14%) , to patients with HIV-
related constitutional symptoms such as unexplained fever (>100degF) of 2 weeks or 
more in duration, or oral candida regardless of CD4 count, and to patients with other 
AIDS-defining diagnoses, such as Kaposi sarcoma. Secondary prophylaxis is given 
in order to prevent a recurrence.  
One double strength (DS) TMP-SMX tablet (containing 160 mg of TMP and 
800mg of SMX) once daily is the first-choice regimen for both primary and secondary 
prophylaxis. Lower doses, one DS TMP-SMX three times weekly or one single 
strength TMP-SMX tablet (containing 80mg of TMP and 400mg of SMX) once daily, 
may be equally effective and have fewer adverse drug reactions. Rash, with or 
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without fever, occurs in ≤20% of patients. Desensitization should be attempted in 
those unable to tolerate TMP-SMX. Alternative, other less effective agents are 
available for prophylaxis, including nebulized pentamidine (Nebupent), 300 mg 
(delivered via a Respirgard II nebulizer) once per month, (once per fortnight in HIV-
infected patients with CD4 counts  100 mg OD (or 50mg 
BID), dapsone 50mg OD with pyrimethamine 75 mg once weekly and leucovorin 
25mg once weekly, or dapsone 200mg with 75 mg pyrimethamine and 25 mg 
leucovorin (all once weekly), and oral atovaquone 750 mg twice daily, with or without 
pyrimethamine 75 mg OD and leucovorin 25mg OD [17]. 
 
Stopping prophylaxis 
The widespread availability and uptake of cART in North America, Europe and 
Australasia has been associated with marked reductions in incidence of many 
opportunistic infections, including PCP, hospital admissions and mortality from HIV 
infection. In most patients, within a few weeks of starting cART, there are rapid 
decreases in plasma HIV RNA and, in parallel, increases in CD4 counts. The US 
Public Health Service/Infectious Disease Society of America recommend that primary 
prophylaxis against PCP may be discontinued in HIV-infected persons who respond 
to cART with an increase in CD4 counts to >
months [17]. Many of these patients will also have reduction in HIV RNA to below the 
limit of detection. Withdrawal of secondary prophylaxis may be carried out, using 
these criteria. If, despite cART, the CD4 lymphocyte count falls to <
and/or the plasma HIV RNA “load” rises, then prophylaxis should be re-instituted 
using the criteria for primary prophylaxis. Clearly, close patient monitoring is needed 
to detect any such changes rapidly.       
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Recent data accrued from a cohort study, a retrospective review and a case 
series show a low incidence of PCP among patients who discontinue or never start 
PCP prophylaxis, who received ART and had CD4 counts between 100-200 cells/µL 
and plasma HIV viral loads <50-400 copies/mL [62][63][64]. Although these data 
support discontinuation of primary PCP prophylaxis in certain patients with CD4 
counts between 100-200 cells/µL, with some experts recommending this approach 
for their patients, this intervention has not yet been widely adopted [17]. 
 
Summary 
The yeast-like fungus Pneumocystis causes Pneumocystis pneumonia (PCP) 
which, despite the widespread availability of specific anti-Pneumocystis prophylaxis 
and of combination antiretroviral therapy (cART) remains a common AIDS-defining 
presentation in the United States and in Europe, and is increasingly recognized 
among persons living in Africa. Pneumocystis cannot be cultured and the “gold 
standard” diagnostic test to diagnose PCP is bronchoscopic alveolar lavage. Use of 
adjunctive biomarkers such as Serum (1-3) ß-D-glucan for diagnosis requires further 
evaluation. Recommended first-line treatment is with TMP-SMX. Mortality from PCP 
in the era of cART is approximately 10-12%. The optimal time to start cART in a 
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Figure 1. CXR showing bilateral diffuse interstitial infiltrates 
Figure 2. CXR showing severe PCP. The patient is intubated and mechanically 
ventilated; there is a left-sided pneumothorax. 
Figure 3a. CXR on admission with PCP 
Figure 3b. CXR (same patient as Figure 3a), after an interval of 3 days, showing 
marked deterioration in radiographic abnormalities. 
Figure 4. CXR showing atypical radiologic appearances; asymmetric infiltrates  
Figure 5. CT showing widespread changes of “ground glass” shadowing.  
 
Cause Explanation 
Severe progressive PCP  
Iatrogenic  Pulmonary edema due to intravenous fluid  
overload when giving TMP-SMX 
IRIS following early initiation of cART 
Side effects of therapy Anemia eg TMP-SMX, 
Methemoglobinemia eg dapsone, primaquine 
Inadequate therapy Incorrect dosage or route of administration 
Adjuvant glucocorticoids not given for moderate 
or severe PCP 
Post-bronchoscopy  Sedation 
Pneumothorax  
Pneumothorax Spontaneous 
Associated with mechanical ventilation 
Co-pathology in lung Bacterial infection  
Pulmonary Kaposi sarcoma 
Intercurrent pulmonary embolism 
Wrong diagnosis Empiric diagnosis of PCP and correct diagnosis  
is another pathology eg bacterial pneumonia 
